

**For Immediate Release**

## **MedX Health Announces US Agreement for Innovative Skin Analysis System, MoleMate™**

*Additional Updates On New Initiatives, and  
Amendment to LOI on H'andy Sana 211 Provided  
at Upcoming AGM scheduled for Thursday, January 27<sup>th</sup>*

**Mississauga, ON – January 12, 2011 – MedX Health Corp., (TSXV.MDX)** a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, announced today that they will update shareholders at the Annual General Meeting of Shareholders, scheduled for Thursday, January 27<sup>th</sup>, 2011 at The National Club, at 303 Bay Street, Toronto, ON, at 4:00 PM (Toronto time) on the following key developments:

1. MedX has signed an agreement for the exclusive distribution rights to sell MoleMate in the US, Canada, and Mexico through a subsidiary of Biocompatibles International plc (LSE:BII.L). It involves the launch of MoleMate in the US, through a network of direct representatives calling on General Practitioners, Dermatologists and skin screening clinics and spas. MoleMate is a skin screening diagnostic aid, which is FDA approved and currently sold in Australia and the UK. MedX anticipates regulatory approval in Canada and Mexico in 2011.
2. Progress report on the exclusive distribution agreement with Vet Novations Canada for the direct promotion of MedX laser and light devices within the veterinary market, outlined in the press release of September 30, 2010.
3. Further details of the launch of a comprehensive smoking cessation program in the USA utilizing laser devices from MedX.
4. Announcements of key developments in its core laser business through RJ Laser and updates on International operations.
5. Amendment of LOI with Medical Marketing Berlin (“MMB”) related to the H’andy sana 211 cell phone with integrated ECG capabilities. The LOI will lapse in its current form and will be replaced by an agreement of cooperation to develop and sublicense the H’andy sana 211 together with MMB for the North American market. MedX shall update the market at regular intervals on progress towards this initiative in 2011. Accordingly, MedX will not issue the 27M common shares contemplated by the LOI as disclosed in the press release of July 29, 2010. Mr. Andy Rösch, Managing Director at MMB will leave the MedX Board but may re-join the MedX Board of Directors if MedX and MMB sign a definitive agreement of cooperation in the future regarding the ECG phone.

“In addition to our strong growth in International sales throughout 2010, in the last quarter of the year we entered into several key distribution agreements, which should accelerate our revenue growth in

2011. We are also continuing to evaluate other medical device opportunities, similar to the rights to the skin analysis system, MoleMate, from Biocompatibles, which will take MedX beyond the traditional small and low growth rehab/sports medicine market into a large rapidly expanding market,” stated Steve Guillen, president and CEO of MedX Health Corp.

## **About MoleMate**

MedX has signed an agreement for the exclusive rights to market and sell Biocompatibles skin screening products in the US, Canada, and Mexico. The agreement is with **Biocompatibles UK Ltd**, the manufacturer of the innovative skin analysis system. MoleMate and its related technologies are currently available and being utilized by physicians in the United Kingdom, and Australia. <http://siascopy.biocompatibles.com>

The technology has been evaluated in three (3) clinical trials which have recruited more than 1500 patients assessed with MoleMate. In a substantial UK primary care trial, the rate of Sensitivity (True Positives) and Specificity (True Negatives), the key yardsticks of diagnostic tests, were 96% and 83% respectively, and compared favourably on both measures with benchmark rates from GPs using conventional techniques of 67% and 75% respectively. (Hunter et al: Data presented at the British Association of Dermatologists, July 2006.)

MoleMate utilizes Siascopy™ composed of (a) a non-invasive, hand held skin analysis system called the Siascope™ and (b) several versions of proprietary software. The device is intended to be used to scan the patient’s skin. Siascopy (Spectrophotometric Intracutaneous Analysis) is a non-invasive skin analysis system, which provides colour bitmaps called ‘Siascans’ that show the relative location of blood, collagen, and pigment in a lesion on the skin.

The Siascope operates by illuminating the skin with LEDs and measuring the intensity of remitted light. Unlike biopsy, Siascopy is non-invasive and provides an array of quantitative measurements of the skin that are displayed in graphical form creating a synthesized image called a Siascan. Each Siascan isolates four (4) critical features (Pigment, Dermal Pigment, Blood Supply, and Collagen) viewed over an 11mm diameter area and displays it in conjunction with a magnified ‘dermoscope’ view of the lesion. This data is extremely useful as an adjunct in the clinical diagnosis of skin lesions and other skin conditions and as an adjunct in the planning of their treatment.

## **About MedX Health Corp.**

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world’s only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX’s strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that

will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its “*Photobandage*™”, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit [www.medXhealth.com](http://www.medXhealth.com)

### **About Biocompatibles International plc ([www.biocompatibles.com](http://www.biocompatibles.com))**

Biocompatibles International plc is a leading medical technology company in the field of drug-device combination products.

Biocompatibles International plc’s shareholders have approved a Scheme of Arrangement under which the company will, subject to Court approval, be acquired by BTG plc. The effective date of this acquisition is expected to be 27 January 2011.

The Oncology Products Division supplies medical devices from facilities in Farnham, UK and Oxford, CT. These include Drug-Eluting Bead Products which are used in more than 40 countries for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer, and other cancers; and Brachytherapy products (Radiation-Delivering Seeds) which are used in the treatment of prostate cancer. Distribution partners include AngioDynamics Inc., Terumo Corporation and Eisai Co. Ltd., plus a clinical collaboration agreement with Bayer Healthcare Pharmaceuticals Inc.

The Licensing Division includes CellMed, in Alzenau, Germany, which is developing a Drug-Eluting Bead product for the treatment of stroke, based on proprietary stem cell technology; a GLP-1 analogue for the treatment of diabetes and obesity partnered with AstraZeneca; and a cosmetic Dermatology Bead partnered with Merz Pharmaceuticals GmbH. Biocompatibles also has a PC Licensing agreement with Medtronic Inc. in the field of Drug-Eluting Stents.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

*The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.*

**Contacts:**

Investors:

Steve Guillen

President and Chief Executive Officer

MedX Health Corp. [info@medxhealth.com](mailto:info@medxhealth.com)

Phone: (905) 670-4428